Literature DB >> 21810604

Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase.

Daniel R Sharda1, Shan Yu, Manujendra Ray, Mario Leonardo Squadrito, Michele De Palma, Thomas A Wynn, Sidney M Morris, Pamela A Hankey.   

Abstract

M1 activation of macrophages promotes inflammation and immunity to intracellular pathogens, whereas M2 macrophage activation promotes resolution of inflammation, wound healing, and tumor growth. These divergent phenotypes are characterized, in part, by the expression of inducible NO synthase and arginase I (Arg1) in M1 versus M2 activated macrophages, respectively. In this study, we demonstrate that the Ron receptor tyrosine kinase tips the balance of macrophage activation by attenuating the M1 phenotype while promoting expression of Arg1 through a Stat6-independent mechanism. Induction of the Arg1 promoter by Ron is mediated by an AP-1 site located 433 bp upstream of the transcription start site. Treatment of primary macrophages with macrophage stimulating protein, the ligand for Ron, induces potent MAPK activation, upregulates Fos, and enhances binding of Fos to the AP-1 site in the Arg1 promoter. In vivo, Arg1 expression in tumor-associated macrophages (TAMs) from Ron(-/-) mice was significantly reduced compared with that in TAMs from control animals. Furthermore, we show that Ron is expressed specifically by Tie2-expressing macrophages, a TAM subset that exhibits a markedly skewed M2 and protumoral phenotype. Decreased Arg1 in TAMs from Ron(-/-) mice was associated with reduced syngeneic tumor growth in these animals. These findings indicate that Ron induces Arg1 expression in macrophages through a previously uncharacterized AP-1 site in the Arg1 promoter and that Ron could be therapeutically targeted in the tumor microenvironment to inhibit tumor growth by targeting expression of Arg1.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21810604      PMCID: PMC4042865          DOI: 10.4049/jimmunol.1003460

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  45 in total

Review 1.  Smoldering and polarized inflammation in the initiation and promotion of malignant disease.

Authors:  Frances Balkwill; Kellie A Charles; Alberto Mantovani
Journal:  Cancer Cell       Date:  2005-03       Impact factor: 31.743

2.  Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.

Authors:  Arnold H Zea; Paulo C Rodriguez; Michael B Atkins; Claudia Hernandez; Sabina Signoretti; Jovanny Zabaleta; David McDermott; David Quiceno; Amanda Youmans; Anne O'Neill; James Mier; Augusto C Ochoa
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

3.  Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease.

Authors:  Pratima Sinha; Virginia K Clements; Suzanne Ostrand-Rosenberg
Journal:  J Immunol       Date:  2005-01-15       Impact factor: 5.422

4.  Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses.

Authors:  Paulo C Rodriguez; David G Quiceno; Jovanny Zabaleta; Blair Ortiz; Arnold H Zea; Maria B Piazuelo; Alberto Delgado; Pelayo Correa; Jason Brayer; Eduardo M Sotomayor; Scott Antonia; Juan B Ochoa; Augusto C Ochoa
Journal:  Cancer Res       Date:  2004-08-15       Impact factor: 12.701

5.  A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships.

Authors:  Ferdinando Pucci; Mary Anna Venneri; Daniela Biziato; Alessandro Nonis; Davide Moi; Antonio Sica; Clelia Di Serio; Luigi Naldini; Michele De Palma
Journal:  Blood       Date:  2009-04-21       Impact factor: 22.113

6.  Deregulated inflammatory response in mice lacking the STK/RON receptor tyrosine kinase.

Authors:  P H Correll; A Iwama; S Tondat; G Mayrhofer; T Suda; A Bernstein
Journal:  Genes Funct       Date:  1997-02

Review 7.  Arginine metabolism: nitric oxide and beyond.

Authors:  G Wu; S M Morris
Journal:  Biochem J       Date:  1998-11-15       Impact factor: 3.857

Review 8.  Blood monocytes: development, heterogeneity, and relationship with dendritic cells.

Authors:  Cedric Auffray; Michael H Sieweke; Frederic Geissmann
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

9.  Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells.

Authors:  S M Morris; D Kepka-Lenhart; L C Chen
Journal:  Am J Physiol       Date:  1998-11

10.  Overexpression of the RON gene in human breast carcinoma.

Authors:  P Maggiora; S Marchio; M C Stella; M Giai; A Belfiore; M De Bortoli; M F Di Renzo; A Costantino; P Sismondi; P M Comoglio
Journal:  Oncogene       Date:  1998-06-04       Impact factor: 9.867

View more
  64 in total

Review 1.  Progress in tumor-associated macrophage (TAM)-targeted therapeutics.

Authors:  Chayanon Ngambenjawong; Heather H Gustafson; Suzie H Pun
Journal:  Adv Drug Deliv Rev       Date:  2017-04-25       Impact factor: 15.470

2.  Genetic ablation of arginase 1 in macrophages and neutrophils enhances clearance of an arthritogenic alphavirus.

Authors:  Kristina A Stoermer; Adam Burrack; Lauren Oko; Stephanie A Montgomery; Luke B Borst; Ronald G Gill; Thomas E Morrison
Journal:  J Immunol       Date:  2012-09-12       Impact factor: 5.422

3.  Relationship between tumor-associated macrophage subsets and CD47 expression in squamous cell carcinoma of the head and neck in the tumor microenvironment.

Authors:  Koichi Sakakura; Hideyuki Takahashi; Kyoichi Kaira; Minoru Toyoda; Takaaki Murata; Hiroshi Ohnishi; Tetsunari Oyama; Kazuaki Chikamatsu
Journal:  Lab Invest       Date:  2016-06-20       Impact factor: 5.662

Review 4.  Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

Review 5.  One microenvironment does not fit all: heterogeneity beyond cancer cells.

Authors:  Ik Sun Kim; Xiang H-F Zhang
Journal:  Cancer Metastasis Rev       Date:  2016-12       Impact factor: 9.264

6.  Myeloid-specific expression of Ron receptor kinase promotes prostate tumor growth.

Authors:  Devikala Gurusamy; Jerilyn K Gray; Peterson Pathrose; Rishikesh M Kulkarni; Fred D Finkleman; Susan E Waltz
Journal:  Cancer Res       Date:  2013-01-17       Impact factor: 12.701

7.  RON receptor tyrosine kinase, a negative regulator of inflammation, is decreased during simian immunodeficiency virus-associated central nervous system disease.

Authors:  Daniele C Cary; Janice E Clements; Andrew J Henderson
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

8.  Local effect of IL-4 delivery on polyethylene particle induced osteolysis in the murine calvarium.

Authors:  Allison J Rao; Christophe Nich; Lakshmi S Dhulipala; Emmanuel Gibon; Roberto Valladares; Stefan Zwingenberger; R Lane Smith; Stuart B Goodman
Journal:  J Biomed Mater Res A       Date:  2012-12-05       Impact factor: 4.396

9.  Immune Suppression Mediated by Myeloid and Lymphoid Derived Immune Cells in the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by HrasG12V and Pten Loss.

Authors:  Lee Ann Jolly; Nicole Massoll; Aime T Franco
Journal:  J Clin Cell Immunol       Date:  2016-09-16

10.  Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity.

Authors:  Henok Eyob; Huseyin Atakan Ekiz; Yoko S Derose; Susan E Waltz; Matthew A Williams; Alana L Welm
Journal:  Cancer Discov       Date:  2013-04-23       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.